Another ADC, sacituzumab govitecan, targets the human trophoblast cell-surface antigen 2 (Trop-2), which is highly expressed in BC, and is coupled with a high drug-to-antibody ratio to SN-38, the active metabolite of irinotecan. The gene discussed is TACSTD2; the disease is breast cancer.